{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:52:34Z","timestamp":1772117554063,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd001951","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,8,28]],"date-time":"2013-08-28T00:00:00Z","timestamp":1377648000000}}],"reference-count":174,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001951.pub2","type":"journal-article","created":{"date-parts":[[2013,8,28]],"date-time":"2013-08-28T06:04:36Z","timestamp":1377669876000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Haloperidol dose for the acute phase of schizophrenia"],"prefix":"10.1002","volume":"2013","author":[{"given":"Lorna","family":"Donnelly","sequence":"first","affiliation":[{"name":"NHS Lothian; Cambridge Street House; 5-7 Cambridge Street Edinburgh Lothian UK EH1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Rathbone","sequence":"additional","affiliation":[{"name":"The University of Sheffield; HEDS, ScHARR; Regent Court 30 Regent Street Sheffield UK S1 4DA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clive E","family":"Adams","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Cochrane Schizophrenia Group; Institute of Mental Health University of Nottingham Innovation Park, Triumph Road, Nottingham UK NG7 2TU"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,8,28]]},"reference":[{"key":"10.1002\/14651858.CD001951.pub2-BIB0001|cit1","unstructured":"Curtis CE Mann M Piscani K Burr G Hitzemann RJ Hirschowitz J A neuroendocrine method of antipsychotic dose reduction in schizophrenia Proceedings of the 148th Annual Meeting of the American Psychiatric Association; 1995 May 20-25; Miami 1995"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/archpsyc.1980.01780190089011","article-title":"Haloperidol for acute schizophrenic patients. An evaluation of three oral regimens","volume":"6","author":"Donlon","year":"1980","journal-title":"Archives of General Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD001951.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1176\/ajp.138.10.1307","article-title":"Cognitive changes in acute schizophrenia with brief neuroleptic treatment","volume":"138","author":"Wahba","year":"1981","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1600-0447.1997.tb09642.x","article-title":"A two-phase, double-blind randomised study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders","volume":"4","author":"Janicak","year":"1997","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0005|cit5","first-page":"83","article-title":"Steady-state plasma level prediction for haloperidol from a single test dose","volume":"27","author":"Javaid","year":"1991","journal-title":"Psychopharmacology Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00004714-199602000-00008","article-title":"Prediction of haloperidol steady-state levels in plasma after a single test dose","volume":"16","author":"Javaid","year":"1996","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"4","author":"Kapur","year":"2000","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001951.pub2-BIB0008|cit8","first-page":"136","article-title":"Treatment of acute and transient psychotic disorders with low and high doses of oral haloperidol","volume":"39","author":"Khanna","year":"1997","journal-title":"Indian Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001951.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000118405","article-title":"Experimental comparison of the effectivity of individually adapted and standardized dosages of haloperidol","volume":"18","author":"Klieser","year":"1987","journal-title":"Neuropsychobiology"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1055\/s-2007-999132","article-title":"Experimental comparison of the efficacy of standardized haloperidol treatment and adequate individual dosages in acute schizophrenic states","volume":"3","author":"Klieser","year":"1992","journal-title":"Fortschritte der Neurologie Psychiatrie"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0011|cit11","first-page":"43","article-title":"Comparison of therapeutic effects between haloperidol and insulin coma for schizophrenia and the optimal blood level of haloperidol","volume":"20","author":"Liang","year":"1987","journal-title":"Chinese Journal of Neurology and Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD001951.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1055\/s-2007-1014680","article-title":"Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients","volume":"21","author":"Louza Neto","year":"1988","journal-title":"Pharmacopsychiatry"},{"issue":"8","key":"10.1002\/14651858.CD001951.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archpsyc.1991.01810320063009","article-title":"Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold","volume":"48","author":"McEvoy","year":"1991","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001951.pub2-BIB0014|cit14","first-page":"97","article-title":"Predictors of therapeutic response to haloperidol in acute schizophrenia","volume":"27","author":"McEvoy","year":"1991","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1055\/s-2007-1019484","article-title":"Haloperidol in acute schizophrenic inpatients. A double-blind comparison of two dosage regimens","volume":"16","author":"Modestin","year":"1983","journal-title":"Pharmacopsychiatria"},{"issue":"4","key":"10.1002\/14651858.CD001951.pub2-BIB0016|cit16","first-page":"17","article-title":"Haloperidol plasma red blood-cell ratios and clinical efficacy","volume":"18","author":"Neborsky","year":"1982","journal-title":"Psychopharmacology Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD001951.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/archpsyc.1981.01780270081011","article-title":"Rapid treatment of acute psychotic symptoms with high-and low-dose haloperidol. Behavioral considerations","volume":"38","author":"Neborsky","year":"1981","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD001951.pub2-BIB0018|cit18","first-page":"157","article-title":"Behavioral prediction of response to haloperidol: a test dose strategy","volume":"43","author":"Neborsky","year":"1982","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0020|cit19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0165-1781(82)90044-0","article-title":"Red-blood-cell plasma haloperidol ratios and antipsychotic efficacy","volume":"6","author":"Neborsky","year":"1982","journal-title":"Psychiatry Research"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0019|cit20","first-page":"10","article-title":"Plasma\/RBC haloperidol ratios and improvement in acute psychotic symptoms","volume":"45","author":"Neborsky","year":"1984","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001951.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1017\/S1461145704004262","article-title":"A randomised, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis","volume":"7","author":"Oosthuizen","year":"2004","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD001951.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00004714-199410000-00003","article-title":"Haloperidol: therapeutic window in schizophrenia","volume":"14","author":"Palao","year":"1994","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0278-5846(94)90032-9","article-title":"Positive versus negative symptoms in schizophrenia: response to haloperidol","volume":"18","author":"Palao","year":"1994","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD001951.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/archpsyc.1996.01830120107019","article-title":"The relationship between plasma haloperidol concentrations and clinical results","volume":"53","author":"Palao","year":"1996","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001951.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00004714-199406000-00006","article-title":"Blood levels of haloperidol and clinical outcome in schizophrenia","volume":"14","author":"Doddi","year":"1994","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD001951.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/archpsyc.1991.01810260074011","article-title":"Dosage of haloperidol for schizophrenia","volume":"48","author":"Rifkin","year":"1991","journal-title":"Archives of General Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD001951.pub2-BIB0027|cit27","first-page":"401","article-title":"A controlled study of haloperidol in chronic schizophrenia","volume":"9","author":"Simpson","year":"1967","journal-title":"Current Therapeutic Research"},{"issue":"3","key":"10.1002\/14651858.CD001951.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0893-133X(96)00186-8","article-title":"Etiologic heterogeneity of the psychoses: is there a dopamine psychosis?","volume":"16","author":"Garver","year":"1997","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD001951.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1176\/ajp.152.8.1210","article-title":"Further evidence of a dose-response threshold for haloperidol in psychosis","volume":"152","author":"Stone","year":"1995","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0030|cit30","unstructured":"Bitter I Volavka J Cooper J Scheurer Camus L Bakall R Haloperidol blood levels and clinical effects in schizophrenia Proceedings of the 8th World Congress of Psychiatry; 1989 Oct 13-19; Athens, Greece 1989"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0165-1781(98)00085-7","article-title":"Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder","volume":"81","author":"Chou","year":"1998","journal-title":"Psychiatry Research"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1176\/ajp.151.1.49","article-title":"Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia","volume":"151","author":"Convit","year":"1994","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001951.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00004714-199204000-00011","article-title":"Plasma drug level and clinical response","volume":"12","author":"Cooper","year":"1992","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD001951.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0010-440X(96)90037-1","article-title":"Dimensions of the brief psychiatric rating scale: an examination of stability during haloperidol treatment","volume":"37","author":"Czobor","year":"1996","journal-title":"Comprehensive Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001951.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0165-1781(92)90077-G","article-title":"Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve","volume":"42","author":"Czobor","year":"1992","journal-title":"Psychiatry Research"},{"issue":"4","key":"10.1002\/14651858.CD001951.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/schbul\/22.4.577","article-title":"Positive and negative symptoms: is their change related?","volume":"22","author":"Czobor","year":"1996","journal-title":"Schizophrenia Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD001951.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/00004714-199310000-00006","article-title":"Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients","volume":"13","author":"Czobor","year":"1993","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0165-1781(97)03076-X","article-title":"Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes","volume":"71","author":"Krakowski","year":"1997","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1001\/archpsyc.1992.01820050018002","article-title":"Haloperidol blood levels and clinical effects","volume":"5","author":"Volavka","year":"1992","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0040|cit40","first-page":"13","article-title":"Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report","volume":"26","author":"Volavka","year":"1990","journal-title":"Psychopharmacology Bulletin"},{"issue":"12","key":"10.1002\/14651858.CD001951.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/archpsyc.1992.01820120087017","article-title":"Neuroleptic treatment, symptoms of schizophrenia, and plasma homovanillic acid concentrations revisited","volume":"49","author":"Volavka","year":"1992","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0165-1781(98)00085-7","article-title":"Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder","volume":"81","author":"Chou","year":"1998","journal-title":"Psychiatry Research"},{"issue":"3","key":"10.1002\/14651858.CD001951.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0010-440X(96)90037-1","article-title":"Dimensions of the Brief Psychiatric Rating Scale: an examination of stability during haloperidol treatment","volume":"37","author":"Czobor","year":"1996","journal-title":"Comprehensive Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD001951.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/schbul\/22.4.577","article-title":"Positive and negative symptoms: is their change related?","volume":"22","author":"Czobor","year":"1996","journal-title":"Schizophrenia Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0045|cit45","first-page":"75","article-title":"Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder","volume":"32","author":"Volavka","year":"1996","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0047|cit46","first-page":"536","article-title":"Haloperidol plasma levels and clinical effects","volume":"31","author":"Volavka","year":"1995","journal-title":"Psychopharmacology Bulletin"},{"issue":"10","key":"10.1002\/14651858.CD001951.pub2-BIB0046|cit47","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/archpsyc.1995.03950220047010","article-title":"Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder","volume":"52","author":"Volavka","year":"1995","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/BF00432033","article-title":"Differential improvements from haloperidol in two types of schizophrenics","volume":"84","author":"Lehmann","year":"1984","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000118122","article-title":"Effects of high and low dosage of haloperidol on the brain in relation to schizophrenic thought disorder","volume":"2-3","author":"Winter","year":"1984","journal-title":"Neuropsychobiology"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF00427590","article-title":"High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin","volume":"67","author":"Bjorndal","year":"1980","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD001951.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1017\/S0767399X0000095X","article-title":"Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools","volume":"2","author":"Boyer","year":"1987","journal-title":"Psychiatrie and Psychobiologie"},{"issue":"6","key":"10.1002\/14651858.CD001951.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00004714-199010060-00003","article-title":"Haloperidol plasma levels and acute clinical change in schizophrenia","volume":"10","author":"Coryell","year":"1990","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD001951.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/BF02247134","article-title":"Reduced haloperidol plasma-concentration and clinical-response in acute exacerbations of schizophrenia","volume":"102","author":"Kelly","year":"1990","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1176\/ajp.155.1.48","article-title":"Haloperidol plasma levels and dose optimization","volume":"155","author":"Coryell","year":"1998","journal-title":"American Journal of Psychiatry"},{"issue":"1-2","key":"10.1002\/14651858.CD001951.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0920-9964(95)95455-I","article-title":"The clinical utility of haloperidol plasma levels","volume":"15","author":"Coryell","year":"1995","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0056|cit56","first-page":"48","article-title":"Blood levels of haloperidol and clinical response","volume":"21","author":"Davis","year":"1985","journal-title":"Psychopharmacology Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD001951.pub2-BIB0057|cit57","first-page":"15","article-title":"Haloperidol dose, plasma levels, and clinical response: a double-blind study","volume":"14","author":"Ericksen","year":"1978","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1001\/archpsyc.1983.01790110023005","article-title":"Thought disorder. The measurement of its changes","volume":"40","author":"Hurt","year":"1983","journal-title":"Archives of General Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD001951.pub2-BIB0059|cit59","first-page":"475","article-title":"Rapid tranquilization: the efficacy of oral concentrate","volume":"46","author":"Dubin","year":"1985","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD001951.pub2-BIB0060|cit60","first-page":"417","article-title":"Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses","volume":"21","author":"Dutoit","year":"1995","journal-title":"Encephale"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1017\/S0033291700009818","article-title":"Drug response patterns as a basis of nosology for the mood-incongruent psychoses (the schizophrenias)","volume":"18","author":"Garver","year":"1988","journal-title":"Psychological Medicine"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0062|cit62","first-page":"62","article-title":"Plasma haloperidol levels and clinical response: confounding variables","volume":"21","author":"Mavroidis","year":"1985","journal-title":"Psychopharmacology Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD001951.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF00427577","article-title":"Clinical response and plasma haloperidol levels in schizophrenia","volume":"81","author":"Mavroidis","year":"1983","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD001951.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00004714-198406000-00004","article-title":"Haloperidol plasma and red blood cell levels and clinical antipsychotic response","volume":"4","author":"Garver","year":"1984","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"19","key":"10.1002\/14651858.CD001951.pub2-BIB0065|cit65","first-page":"1309","article-title":"Dogmatil and haloperidol for the treatment of schizophrenia. Double blind cross-over study of therapeutic effectiveness, side effects and plasma concentrations","volume":"61","author":"Gerlach","year":"1985","journal-title":"Semaine des Hopitaux"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0920-9964(96)00074-6","article-title":"The Dose Reduction in Schizophrenia (DORIS) Study: a final report","volume":"23","author":"Hirschowitz","year":"1997","journal-title":"Schizophrenia Research"},{"issue":"5","key":"10.1002\/14651858.CD001951.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0893-133X(96)00018-8","article-title":"Nicotine-haloperidol interactions and cognitive performance in schizophrenics","volume":"15","author":"Levin","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0068|cit68","unstructured":"Ortega-Soto HA Fernandez AE Pinedo H De La Torre P Brunner E Apiquian R Clinical trial of haloperidol threshold doses Proceedings of the 146th Annual Meeting of the American Psychiatric Association; 1993 May 22-27; San Francisco 1993"},{"issue":"3S Pt 2","key":"10.1002\/14651858.CD001951.pub2-BIB0069|cit69","first-page":"140S","article-title":"Therapeutic minimum dose of haloperidol in schizophrenia","volume":"10","author":"Ortega-Soto","year":"1994","journal-title":"Neuropsychopharmocology"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0070|cit70","unstructured":"Ortega-Soto HA Fernandez AE Pinedo H De La Torre P Brunner E Apiquian R Clinical trial of haloperidol threshold doses Patient Care for the 21st Century: Asserting Professional Values with Economic Restraints. Proceedings of the 146th Annual Meeting of the American Psychiatric Association; 1993, May 22-27; San Francisco 1993"},{"issue":"3","key":"10.1002\/14651858.CD001951.pub2-BIB0071|cit71","first-page":"112","article-title":"Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia","volume":"35","author":"Reschke","year":"1974","journal-title":"Diseases of the Nervous System"},{"issue":"4","key":"10.1002\/14651858.CD001951.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1600-0447.1989.tb10269.x","article-title":"Clinical implications of determination of plasma haloperidol levels","volume":"79","author":"Santos","year":"1989","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"4","key":"10.1002\/14651858.CD001951.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0006-3223(89)90054-1","article-title":"Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia","volume":"26","author":"Santos","year":"1989","journal-title":"Biological Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD001951.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/0278-5846(89)90043-2","article-title":"Determination of plasma haloperidol concentrations by radioreceptor assay in schizophrenia-clinical utility","volume":"13","author":"Santos","year":"1989","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0075|cit75","unstructured":"Sim CB Lee YC Hwang JP Haloperidol for schizophrenic inpatients with three doseage regimens Psychiatry Today: Accomplishments and Promises; Proceedings of the 8th World Congress of Psychiatry; 1989, Oct 12-19; Athens, Greece London Excerpta Medica International Congress Series 899 1989 817"},{"issue":"8","key":"10.1002\/14651858.CD001951.pub2-BIB0081|cit76","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/archpsyc.1985.01790310103015","article-title":"Plasma haloperidol levels-clinical-response and fancy mathematics - reply","volume":"42","author":"Smith","year":"1985","journal-title":"Archives of General Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD001951.pub2-BIB0082|cit77","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1001\/archpsyc.1985.01790310107017","article-title":"The interpretation of plasma haloperidol concentrations-reply","volume":"42","author":"Smith","year":"1985","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0076|cit78","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1987.tb02745.x","article-title":"Cortical atrophy and white matter density in the brains of schizophrenics and clinical-response to neuroleptics","volume":"75","author":"Smith","year":"1987","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"11","key":"10.1002\/14651858.CD001951.pub2-BIB0077|cit79","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/archpsyc.1983.01790220034006","article-title":"Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays","volume":"41","author":"Smith","year":"1984","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0078|cit80","first-page":"52","article-title":"Haloperidol and thioridazine drug levels and clinical-response in schizophrenia-comparison of gas-liquid-chromatography and radioreceptor drug level assays","volume":"21","author":"Smith","year":"1985","journal-title":"Psychopharmacology Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD001951.pub2-BIB0079|cit81","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0165-1781(85)90019-8","article-title":"Lateral ventricular enlargement and clinical-response in schizophrenia","volume":"14","author":"Smith","year":"1985","journal-title":"Psychiatry Research"},{"issue":"4","key":"10.1002\/14651858.CD001951.pub2-BIB0080|cit82","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF00429663","article-title":"Comparative efficacy of red-cell and plasma haloperidol as predictors of clinical-response in schizophrenia","volume":"85","author":"Smith","year":"1985","journal-title":"Psychopharmacology"},{"issue":"12","key":"10.1002\/14651858.CD001951.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/archpsyc.1987.01800240086016","article-title":"Plasma haloperidol levels and clinical response","volume":"44","author":"Smith","year":"1987","journal-title":"Archives of General Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD001951.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/archpsyc.1990.01810200062009","article-title":"A controlled dose comparison of haloperidol in newly admitted schizophrenic patients","volume":"47","author":"Putten","year":"1990","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001951.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00004714-200004000-00020","article-title":"High dose treatment with haloperidol: the effect of dose reduction","volume":"20","author":"Volavka","year":"2000","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0086|cit86","unstructured":"Volavka J Cooper TB Czobor P Lindenmayer JP Citrome LL Mohr P Haloperidol blood levels and effects in schizophrenia Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego 1997"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0087|cit87","doi-asserted-by":"crossref","unstructured":"Baker R Mack R Morris D Sebree T Kashkin KB The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients Proceedings of the 9th European College of Neuropsychopharmacology Congress; 1996 Sep 21-25; Amsterdam, Netherlands 1996","DOI":"10.1016\/0924-977X(96)83224-X"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0006-3223(96)84277-6","article-title":"Efficacy and safety of three doses of sertindole and haloperidol in schizophrenic patients","volume":"39","author":"Bark","year":"1996","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0089|cit89","unstructured":"Larson GL Mack RJ Zborowski J Morris DD Sebree TB Wallin BA Three doses each of sertindole and haloperidol in schizophrenics Proceedings of the 10th World Congress of Psychiatry; 1996 Aug 23-28; Madrid, Spain 1996"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0090|cit90","doi-asserted-by":"crossref","unstructured":"Tamminga C Mack R Zborowski J Morris D Sebree T Wallin B Efficacy and safety of three doses of sertindole and haldol in schizophrenic patients Proceedings of the 20th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1996 Jun 23-27; Melbourne, Australia 1996","DOI":"10.1016\/0924-977X(96)87584-5"},{"issue":"6","key":"10.1002\/14651858.CD001951.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1176\/ajp.154.6.782","article-title":"Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole study group","volume":"154","author":"Zimbroff","year":"1997","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0092|cit92","doi-asserted-by":"crossref","unstructured":"Zimbroff DL Mack RJ Morris DD Silber CJ The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients Schizophrenia 1996: Breaking Down the Barriers. Proceedings of the 4th International Conference; 1996 Oct 6-9; Vancouver 1996","DOI":"10.1016\/0924-977X(96)83224-X"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0093|cit93","doi-asserted-by":"crossref","unstructured":"Zimbroff DL Mack RJ Zborowski JN Morris DD Sebree TB Wallin BA The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9; New York 1996","DOI":"10.1016\/0924-977X(96)83224-X"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","article-title":"A depression rating scale for schizophrenics","volume":"3","author":"Addington","year":"1990","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0096|cit96","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia","volume":"154 Suppl 4","author":"American Psychiatric Association","year":"1997","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1192\/S000712500029260X","article-title":"Methodological and design issues in clinical trials of new neuroleptics: an overview","volume":"Suppl 22","author":"Awad","year":"1993","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0098|cit98","first-page":"22","article-title":"Cost-utility analysis in schizophrenia","volume":"60 Suppl 3","author":"Awad","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001951.pub2-BIB0099|cit99","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001945","article-title":"Ziprasidone for schizophrenia and severe mental illness","author":"Bagnall","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD001951.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1176\/ajp.141.6.748","article-title":"Dissimilar dosing with high-potency and low-potency neuroleptics","volume":"141","author":"Baldessarini","year":"1984","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/archpsyc.1988.01800250095013","article-title":"Significance of neuroleptic dose and plasma level in the pharmacologic treatment of psychoses","volume":"45","author":"Baldessarini","year":"1988","journal-title":"Archives of General Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD001951.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1176\/ajp.152.7.1038","article-title":"Hospital use of antipsychotic agents in 1989 and 1993: stable dosing with decreased length of stay","volume":"152","author":"Baldessarini","year":"1995","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001951.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/070674379403900203","article-title":"Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms","volume":"39","author":"Bezchlibnyk-Butler","year":"1994","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD001951.pub2-BIB0105|cit105","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1017\/S003329170002729X","article-title":"Antipsychotic drugs: is more worse? A meta-analysis of the published randomised control trials","volume":"24","author":"Bollini","year":"1994","journal-title":"Psychological Medicine"},{"issue":"2","key":"10.1002\/14651858.CD001951.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1742-1241.2010.02587.x","article-title":"Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved antipsychotic","volume":"65","author":"Citrome","year":"2011","journal-title":"International Journal of Clinical Practise"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0108|cit108","unstructured":"Clarke M Oxman AD (editors) Cochrane Reviewer's Handbook Cochrane Database of Systematic Reviews 2002"},{"issue":"9","key":"10.1002\/14651858.CD001951.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1176\/ajp.154.9.1243","article-title":"Time to clozapine response in a standardized trial","volume":"154","author":"Conley","year":"1997","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0110|cit110","first-page":"25","article-title":"Canadian clinical practice guidelines for the treatment of schizophrenia","volume":"2 Suppl 43","author":"Canadian Psychiatric Association","year":"1998","journal-title":"Canadian Journal of Psychiatry-Revue Canadienne De Psychiatrie"},{"issue":"6","key":"10.1002\/14651858.CD001951.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics","volume":"60","author":"Davis","year":"2003","journal-title":"Archives General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD001951.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2710.1996.tb01143.x","article-title":"Haloperidol blood levels and clinical outcome: a meta-analysis of studies relevant to testing the therapeutic window hypothesis","volume":"21","author":"Oliveira","year":"1996","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0113|cit113","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town, South Africa 2000"},{"issue":"6","key":"10.1002\/14651858.CD001951.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomised trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0116|cit116","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001359.pub2","article-title":"Olanzapine for schizophrenia","author":"Duggan","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7109","key":"10.1002\/14651858.CD001951.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: sulpiride versus placebo for schizophrenia 18\/22 methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0119|cit119","doi-asserted-by":"crossref","unstructured":"Emsley R McCreadie R Livingston M De Smedt G Lemmens P Risperidone in the treatment of first-episode schizophrenic patients with schizophreniform disorder: a double blind study Congress of the International Academy for Biomedical and Drug Research on Critical Issues in the Treatment of Schizophrenia 1995","DOI":"10.1016\/0924-977X(95)90596-6"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/archpsyc.1978.01770310043002","article-title":"A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia","volume":"35","author":"Endicott","year":"1978","journal-title":"Archives of General Psychiatry"},{"issue":"13","key":"10.1002\/14651858.CD001951.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1503\/cmaj.1041064","article-title":"Modern antipsychotic drugs: a critical overview","volume":"172","author":"Gardner","year":"2005","journal-title":"CMAJ"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0122|cit122","unstructured":"Geddes J Royal College of Psychiatrists guidelines on for the care of those with schizophrenia The Schizophrenia Trials Meeting; 1999 May 5-7; Stratford-upon-Avon, UK 1999"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0123|cit123","first-page":"23","article-title":"Formulary decisions and health economics","volume":"59 Suppl 19","author":"Glazer","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0125|cit125","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"issue":"4","key":"10.1002\/14651858.CD001951.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/schbul\/23.4.567","article-title":"Neuroleptic intolerance","volume":"23","author":"Hansen","year":"1997","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0128|cit128","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/archpsyc.1973.01750310038007","article-title":"Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates","volume":"28","author":"Hogarty","year":"1973","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD001951.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archpsyc.1974.01760170005001","article-title":"Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates","volume":"31","author":"Hogarty","year":"1974","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1600-0447.1993.tb03480.x","article-title":"Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations","volume":"88","author":"Hoyberg","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1600-0447.1995.tb09781.x","article-title":"Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel group trial","volume":"91","author":"Huttunen","year":"1995","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomised clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0135|cit135","unstructured":"Jadad A Meta-analysis making the same mistakes as trials Proceedings of the 2nd Symposium on Systematic Reviews: Beyond the Basics; 1999 Jan 5-7; Oxford, UK 1999"},{"issue":"5","key":"10.1002\/14651858.CD001951.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/00005650-199305000-00005","article-title":"Antipsychotic drug exposure in a health maintenance organization","volume":"31","author":"Johnson","year":"1993","journal-title":"Medical Care"},{"issue":"2","key":"10.1002\/14651858.CD001951.pub2-BIB0137|cit137","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003082.pub2","article-title":"Haloperidol versus placebo for schizophrenia","author":"Joy","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJM199601043340109","article-title":"Schizophrenia","volume":"334","author":"Kane","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD001951.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1176\/ajp.153.7.948","article-title":"High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study","volume":"153","author":"Kapur","year":"1996","journal-title":"American Journal of Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD001951.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1176\/ajp.154.11.1525","article-title":"PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia","volume":"154","author":"Kapur","year":"1997","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001951.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/sj.mp.4000327","article-title":"A new framework for investigating antipsychotic action in humans: lessons from pet imaging","volume":"3","author":"Kapur","year":"1998","journal-title":"Molecular Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001951.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0143|cit143","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"2","key":"10.1002\/14651858.CD001951.pub2-BIB0144|cit144","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000440","article-title":"Risperidone versus typical antipsychotic medication for schizophrenia","author":"Kennedy","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD001951.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2125.1995.tb05791.x","article-title":"Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden","volume":"40","author":"Kiivet","year":"1995","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0146|cit146","unstructured":"Kudo Y Nomura J Ikawa G Nakajima T Saito M Sakai T Clinical trial of quetiapine in schizophrenia-efficacy and tolerability of quetiapine: a comparative double-blind study with mosapramine in schizophrenic patients Proceeding of the Annual Meeting of the World Psychiatric Association; 1999 Aug; Hamburg, Germany 1999"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","article-title":"Efficacy and extra-pyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomised controlled trials","volume":"35","author":"Leucht","year":"1999","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"Part 2","key":"10.1002\/14651858.CD001951.pub2-BIB0150|cit150","first-page":"152-9S, 166-8S","article-title":"Sedation in acute and chronic agitation","volume":"6","author":"Levy","year":"1996","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1002\/14651858.CD001951.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/archpsyc.1993.01820170047006","article-title":"Time course and biologic correlates of treatment response in first-episode schizophrenia","volume":"50","author":"Lieberman","year":"1993","journal-title":"Archives of General Psychiatry"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001951.pub2-BIB0152|cit152","first-page":"21","article-title":"Facilitating compliance with antipsychotic medication","volume":"59","author":"Marder","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD001951.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0278-5846(97)00099-7","article-title":"Dose-response relationships for the antipsychotic effects and parkinsonian side-effects of typical neuroleptic drugs: practical and theoretical implications","volume":"21","author":"Miller","year":"1997","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD001951.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"494","DOI":"10.2165\/00003088-199528060-00007","article-title":"Emergency treatment of psychotic symptoms. Pharmacokinetic considerations for antipsychotic drugs","volume":"28","author":"Milton","year":"1995","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0156|cit156","unstructured":"Murasaki M Koyama T Yamauchi T Yagi MG Ushijima S Kamijima K Clinical evaluation of quetiapine in schizophrenia-efficacy and tolerability of quetiapine compared with haloperidol in patients with schizophrenia Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany 1999"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1600-0447.1997.tb10162.x","article-title":"A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"96","author":"Peuskens","year":"1997","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"5","key":"10.1002\/14651858.CD001951.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1600-0447.1993.tb03379.x","article-title":"Antipsychotic drug prescription in general practice in Italy","volume":"87","author":"Raschetti","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"6","key":"10.1002\/14651858.CD001951.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1176\/ajp.146.6.726","article-title":"Changing patterns of neuroleptic dosage over a decade","volume":"146","author":"Reardon","year":"1989","journal-title":"American Journal of Psychiatry"},{"issue":"20","key":"10.1002\/14651858.CD001951.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1001\/jama.290.20.2693","article-title":"Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia","volume":"290","author":"Rosenheck","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0163|cit163","first-page":"359","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Sch\u00fcnemann","year":"2011"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0165|cit165","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000967.pub2","article-title":"Quetiapine for schizophrenia","author":"Srisurapanont","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD001951.pub2-BIB0166|cit166","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000284.pub2","article-title":"Chlorpromazine versus placebo for those with schizophrenia","author":"Thornley","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7167","key":"10.1002\/14651858.CD001951.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1136\/bmj.317.7167.1181","article-title":"Content and quality of 2000 controlled trials in schizophrenia over 50 years","volume":"317","author":"Thornley","year":"1998","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD001951.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"2","key":"10.1002\/14651858.CD001951.pub2-BIB0169|cit169","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003441.pub2","article-title":"'As required' medication regimens for seriously mentally ill people in hospital","author":"Whicher","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0170|cit170","unstructured":"World Health Organization WHO Model Lists of Essential Medicines, 2011 www.who.int\/medicines\/publications\/essentialmedicines\/en\/ (accessed 20 June 2013)"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0171|cit171","first-page":"81","article-title":"Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia","volume":"37 Suppl 4","author":"Williams","year":"1999","journal-title":"Medical Care"},{"issue":"1","key":"10.1002\/14651858.CD001951.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0193-953X(05)70366-X","article-title":"Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia","volume":"21","author":"Zito","year":"1998","journal-title":"Psychiatric Clinics of North America"},{"key":"10.1002\/14651858.CD001951.pub2-BIB0173|cit173","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"3","key":"10.1002\/14651858.CD001951.pub2-BIB0174|cit174","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001951","article-title":"Haloperidol dose for the acute phase of schizophrenia","author":"Waraich","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD001951.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T13:18:30Z","timestamp":1729862310000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001951.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,8,28]]},"references-count":174,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001951.pub2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718087863.793484174","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,28]]}}}